CYP2C19 and cerebrovascular disorder: Populations varied: the studies of Genomadix (Spartan) CYP2C19 tests mainly recruited patients undergoing PCI, the GMEX System study recruited healthy people and people with cardiovascular and cerebrovascular diseases and the Genedrive study tested donor specimens.